GreenAppleInvestments

$BX bulls have one strong argument our models might miss: The 'option value' of carried interest during market recoveries. Performance fees can surge violently when exit windows reopen. Our normalized approach smooths this away, potentially understating upside. But even accounting for this, paying $117 for a $23 base case requires perfect execution.

The single question that will determine Blackstone's next five years: Is the current drawdown in realizations and fundraising cyclical or structural? Cyclical = potential 3x upside from our bear case Structural = fee compression accelerates, margins fade permanently Q2 earnings should provide the first real clues.

Want alternatives exposure? Here's why we're cautious on $BX at current levels: → Trading at 8.3x EV/Revenue vs peers at 3-6x → Market cap demands $155B enterprise value to justify → Our conservative model shows $39B operating value KKR and Apollo offer similar exposure without the valuation stretch.

Buried in Blackstone's partnership structure is the real valuation puzzle. Our DCF uses 1.22B total diluted economic shares — not just the Class A shares most investors count. This includes all partnership units and profit interests. Per-share economics get diluted as the platform grows. Factor that in or overpay by design.

$BX trades like a perpetual fee annuity. But look closer at the cash flows: → FCF swung from $6.1B to $3.4B to $4.4B across recent years → Pretax income ranged $3.0B to $7.2B on similar revenue → Payout ratio sits at 122% That's not an annuity. That's cyclicality dressed up as stability.

The most important number for $BX isn't AUM growth or performance fees. It's fee-rate compression. Measured in basis points, felt in terminal value. Our models show even modest compression (48% to 44% pretax margins) drops intrinsic value from $23 to $14. This quiet killer compounds over decades.

Everyone calls Blackstone a sleep-at-night alternative asset compounder. They're right about the quality — 29.5% ROE speaks for itself. But here's the uncomfortable math: our stress-testing across 10,000 scenarios shows the current price above what the business generates in cash flow 100% of the time. Quality doesn't always equal good value.

$BX down 11% this year despite 29.5% ROE and 38% operating margins. Our analysis suggests the market is pricing in a perfect world: → Sustained high margins with minimal fee compression → Perpetual capital growth continuing indefinitely → Performance fees returning to boom levels Even our bull case lands at $34/share. At $117, you're paying for outcomes that may not exist.

Three numbers that will determine MarketAxess's next 5 years: 1. Fee-per-million trend (stabilizing vs. compressing) 2. Information services growth rate (data offsetting venue pressure) 3. Operating expense discipline (margins holding low-40s) Base case requires all three to cooperate. At $137, you're getting paid to underwrite that defense—but it's not guaranteed.

The bear case on MarketAxess isn't dramatic—it's insidious. Structural fee compression + protocol mix shifts could quietly drift EBIT margins from 43% to 41% over several years. Looks trivial quarter-to-quarter. But in a long-duration DCF? That margin drift is worth roughly $30-40 per share. The slow leak matters more than headline volume growth.

Want electronic trading exposure? Here's why we prefer MarketAxess over Tradeweb right now. Tradeweb: 10.0x EV/Revenue, 23.3x forward P/E MarketAxess: 5.4x EV/Revenue, 15.3x forward P/E MKTX trades at a clear discount despite comparable margins. You're being paid via lower multiples to bet on monetization defense—risk/reward looks better here.

Stress-tested MarketAxess across 10,000 scenarios using residual income models. The result: In 0% of scenarios does current price exceed intrinsic value Median value: $256 10th percentile: $201 Biggest value driver? Cost of equity assumptions ($84 swing), followed by earnings retention and terminal returns on equity. Even conservative cases suggest meaningful undervaluation.

MarketAxess faces a classic marketplace dilemma: every efficiency improvement that benefits customers tends to reduce fee-per-unit. Automation, portfolio trading, tighter spreads = great for institutions, challenging for the tollbooth operator. At $137 vs our $174 base value, the market is already pricing significant monetization pressure. Question: too pessimistic or appropriately sober?

For $MKTX, the most important number isn't trading volume growth. It's revenue yield sustainability. Fee-per-million compression can quietly reset the entire valuation framework: → Same relevance, more volume → Slightly worse economics each year → Eventually, multiple rerates Watch upcoming quarters for yield stabilization signals—that's where the thesis lives or dies.

Everyone calls fixed-income trading electronification a tailwind. We see a more nuanced story for MarketAxess. The real battleground isn't venues vs. traditional trading—it's who owns the workflow layer: → Desktop/routing control = pricing power → Venue-only model = price taker status MarketAxess has liquidity and data advantages, but workflow wars determine long-term monetization.

$MKTX down 37% while generating 43.5% operating margins and $324M free cash flow. Something doesn't add up. The market is pricing this electronic bond trading platform like fee compression is accelerating—but our analysis shows the discount may be overdone. Key tension: protocol shifts (more automation, portfolio trading) grow volumes while potentially lowering revenue yield. The question isn't whether electronification continues—it's who captures the economics.

Distribution businesses can't scale margins forever, right? Tell that to $AVTR. This company just held $439M in free cash flow through a revenue downcycle — from $7.5B revenue in FY2022 to $6.6B today. Everyone's obsessing over the 40% operating income decline. But here's what they're missing: the cash never broke. → FCF stayed positive: $710M → $724M → $692M → $439M → Net debt of $3.54B isn't pretty, but it's manageable at these cash levels The real question: is this a leveraged distributor or a validated consumables play wearing distributor clothes?

The bear case on $AVTR isn't complicated: what if "temporary" demand weakness becomes permanent? Weak sponsor funding plus CDMO overcapacity could mean years of pricing pressure. Our analysis shows this scenario drops intrinsic value to $4.50. But here's what the bears miss: even in our stress case, free cash flow stays positive. Leverage matters, but cash flow matters more.

Everyone wants bioprocessing exposure after the CDMO massacre. Here's the contrarian question our team keeps asking: What if Avantor's "boring" distribution business is actually the feature, not the bug? Validated consumables are sexy when biotech funding flows. Distribution pays the bills when it doesn't. Sometimes you want the tortoise, not the hare.

The market's pricing in exactly our base case recovery for $AVTR. Our DCF enterprise value: $8.5B Market's enterprise value: $8.7B Translation: modest revenue growth returning, margins recovering to ~11%, steady deleveraging. No heroics required, but no room for disappointment either. When price meets intrinsic value, returns come from execution, not valuation rescue.